

Request under Freedom of Information Act 2000

Request Ref: NGFOI 19/20: 018

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 09/04/2019.

I am pleased to be able to provide you with the following information:

1 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);
If you do not treat, where do you refer these patients ?

Drug Name	Patient Totals
Axinitib	7
Cabozantinib	*
Everolimus	0
Levatinib + Everolimus	0
Nivolumab	*
Nivolumab + Ipilimumab	0
Pazopanib	11
Sunitinib	13
Temsirolimus	0
Tivozanib	*

In accordance with the Freedom of Information Act, Exemption section 40 (Personal Information) has been applied. Due to the low numbers involved we have withheld the exact numbers to protect the identities of individuals.

While the Trust acknowledges that it is desirable to make information as freely available as possible the release of this information would be unfair to the individuals concerned and would contravene the rights of the individual under the Data Protection Act.

The information requested is therefore held exempt from disclosure under section 40 (Personal Information) of the Freedom of Information Act.

2 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma ? **None**
If you do not treat, where do you refer these patients ?

We do not treat Melanoma patients with chemotherapy at NGH. These patients are usually referred to Leicester, unless the patient chooses to go somewhere else.

Drug Name	Patient Totals
Bevacizumab	
Dabrafenib	
Dabrafenib + Trametinib	

<i>Dacarbazine (DTIC)</i>	
<i>Densoumab</i>	
<i>Encorafenib with Binimetinib</i>	
<i>Ipilimumab</i>	
<i>Nivolumab</i>	
<i>Nivolumab + Ipilimumab</i>	
<i>Pembrolizimab</i>	
<i>Tratmetinib</i>	
<i>Vemurafenib</i>	
<i>Vemurafenib + Cobimetinib</i>	

2a – In the past 3 months, how many Melanoma patients were BRAF+ ? **None**

3 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC);
 If you do not treat, where do you refer these patients ?

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not hold the information that you have requested. Whilst we do hold information for Malignant Neoplasm of Liver and Intrahepatic Cholangiocarcinoma, we do not separate this into subcategory level specific to Liver Cancer (Hepatic Cell – HCC).

<i>Drug Name</i>	<i>Patient Totals</i>
<i>Bevacizumab</i>	
<i>Cisplatin</i>	
<i>Doxorubicin</i>	
<i>Everolimus</i>	
<i>Lapatinib</i>	
<i>Lenvantinib</i>	
<i>Sorafenib</i>	
<i>Sunitinib</i>	

4 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Thyroid Cancer;
 If you do not treat, where do you refer these patients ?

<i>Drug Name</i>	<i>Patient Totals</i>
<i>Axitinib</i>	0
<i>Cabozantinib</i>	0
<i>Lenvantinib</i>	0
<i>Pazopanib</i>	0
<i>Sorafenib</i>	0
<i>Sunitinib</i>	0
<i>Vandetanib</i>	0